Vise Technologies Inc. Acquires Shares of 29,159 Boston Scientific Corporation $BSX

Vise Technologies Inc. bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 29,159 shares of the medical equipment provider’s stock, valued at approximately $1,245,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Boston Scientific in the second quarter valued at approximately $998,000. E Fund Management Co. Ltd. bought a new position in Boston Scientific during the 2nd quarter worth $498,000. Pasadena Private Wealth LLC acquired a new position in Boston Scientific in the 2nd quarter valued at $250,000. Asahi Life Asset Management CO. LTD. bought a new stake in shares of Boston Scientific during the 2nd quarter valued at $433,000. Finally, Aurora Investment Counsel acquired a new stake in shares of Boston Scientific during the 2nd quarter worth $1,872,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on BSX. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research report on Thursday, May 28th. BTIG Research reduced their price objective on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 29th. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. Finally, Royal Bank Of Canada cut their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $71.62.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $50.39 on Friday. Boston Scientific Corporation has a one year low of $42.20 and a one year high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market cap of $73.03 billion, a price-to-earnings ratio of 20.40, a PEG ratio of 1.10 and a beta of 0.56. The firm has a 50 day simple moving average of $46.34 and a 200 day simple moving average of $57.86.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.03. The firm had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The company’s revenue was up 7.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts predict that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling

In other news, Director David C. Habiger bought 2,100 shares of the stock in a transaction on Wednesday, August 5th. The stock was acquired at an average price of $47.59 per share, with a total value of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney acquired 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The stock was acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought 194,522 shares of company stock worth $9,385,210 in the last 90 days. Insiders own 0.34% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.